Regenxbio Inc To Discuss RGX-314 For The Treatment Of Wet AMD Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the REGENXBIO Update Call on RGX-314 for the Treatment of wet AMD. (Operator Instructions)
I would now like to turn the call over to your host, Ken Mills, Chief Executive Officer. You may begin.
Good morning, everyone. Thanks for joining us so early. We're pleased this morning to be sharing new interim data from our Phase II AAVIATE trial of RGX-314 for the treatment of patients with wet AMD using suprachoroidal delivery.
Here on the call this morning to discuss the data are Dr. Steve Pakola, our Chief Medical Officer; Dr. Arshad Khanani, who will be joining us to share his thoughts and for Q&A. Dr. Khanani is an undisputed leader in the retina community and a strong advocate for patients. He's the Director of Clinical Research at Sierra Eye Associates, preeminent retinal surgeons and one of the clinical investigators involved in our RGX-314 clinical program. Throughout the call, you can follow along with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
